容积剂量参数V20和V30在评估和预测同步放化疗治疗局部晚期非小细胞肺癌致放射性肺损伤中的应用

doi:10.13481/j.1671-587x.20150131

吉林大学学报(医学版) ›› 2015, Vol. 41 ›› Issue (01): 160-164.doi: 10.13481/j.1671-587x.20150131

容积剂量参数V20和V30在评估和预测同步放化疗治疗局部晚期非小细胞肺癌致放射性肺损伤中的应用

杜敏娟¹, 姜振宇², 徐晓光³, 李洁⁴, 张进²

1. 吉林医药学院附属医院肿瘤科, 吉林吉林 132001;
2. 吉林大学第一医院风湿免疫科, 吉林长春 130021;
3. 吉化集团公司总医院呼吸内科, 吉林吉林 132021;
4. 吉化集团公司总医院普外科, 吉林吉林 132021

收稿日期:2014-09-04 发布日期:2015-01-30
通讯作者: 姜振宇,教授,博士研究生导师(Tel:0431-88782060,E-mail:512517403@qq.com) E-mail:512517403@qq.com
作者简介:杜敏娟(1981-),女,辽宁省铁岭市人,主治医师,医学硕士,主要从事肺癌同步放化疗治疗方面的研究。
基金资助:
吉林省科技厅科研基金资助课题(20090454)

Application of V20 and V30 volume dose parameters in evaluating and forecasting radioactive lung injury caused by concurrent radiochemotherapy in treatment of locally advanced non-small cell lung cancer

DU Minjuan¹, JIANG Zhenyu², XU Xiaoguang³, LI Jie⁴, ZHANG Jin²

1. Department of Oncology, Affiliated Hospital, Jilin Medical College, Jilin 132001, China;
2. Department of Rheumatology, First Hospital, Jilin University, Changchun 130021, China;
3. Department of Respiratory Medicine, General Hospital, Jilin Chemical Group Corporation, Jilin 132021, China;
4. Department of General Surgery, General Hospital, Jilin Chemical Group Corporation, Jilin 132021, China

Received:2014-09-04 Published:2015-01-30

摘要/Abstract

摘要：

目的: 探讨剂量体积直方图(DVH)容积剂量(Vd)参数V20和V30(双肺接受20和30 Gy剂量照射的肺体积占全肺总体积的百分比)与同步放化疗治疗局部晚期非小细胞肺癌(LANSCLC)所致的放射性肺损伤的关系,明确能否用V20和V30评价和预测同步放化疗放射性肺损伤发生率。方法: 入选本研究的同步放化疗患者36例,均采用三维适形放疗(3D-CRT),常规分割2 Gy/次,5次/周,总剂量60~66 Gy/30~33 F。有锁骨上淋巴结转移者也在常规放疗时另设野,给予电子线局部补量至60~70 Gy/7周。化疗方案为紫杉醇+卡铂(Taxol+Carboplatin),Taxol 135 mg·m^-2,第1天、第22天;Carboplatin 药时曲线下面积(AUC)=6 g·L^-1·min^-1,第1天、第22天化疗。将2级以上放射性肺损伤分级与V20和V30进行相关分析,并根据全肺V20平均值(25.32%)及V30平均值(18.17%)分别进行分组,包括V20≤25%、V20>25%组和V30≤18%、V30>18%组,比较各组患者2级以上放射性肺损伤发生率。结果: 2级以上放射性肺损伤的分级与V20和V30均呈正相关关系 (r=0.740,P<0.05;r=0.705,P<0.05)。V20≤25%和V20 > 25%组2级以上放射性肺损伤的发生率分别为17.64%和52.63%,组间比较差异有统计学意义(P<0.05);V30≤18%和V30>18%组2级以上放射性肺损伤的发生率分别为16.67%和55.56%,组间比较差异有统计学意义(P<0.05)。结论: 容积剂量参数V20和V30可用于评估和预测同步放化疗后放射性肺损伤的发生率,同步放化疗中V20 > 25%及V30 > 18%时放射性肺损伤的发生率明显增高,需要对治疗计划进行修改,甚至放弃所设计的治疗计划。

关键词: 癌, 非小细胞肺, 同步放化疗, 放射性肺损伤, 容积剂量参数

Abstract:

Objective To research the relationship between volume dose(Vd)parameters V20 and V30 of dose volume histogram(DVH)and radioactive lung injury caused by concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer(LANSCLC), and to clear whether V30 and V20 could evaluate the probability of radioactive lung injury in chemoradiation. Methods 36 patients treated with concurrent radiochemotherapy were retrospectively analyzed.Radiotherapy Ways : 3D-CRT, the conventional fractionation was 2 Gy/frack(F), 5 times/week, the total dose in concurrent chemoradiotherapy group was 66-70 Gy/30-33 F and the total dose in sequential chemoradiotherapy group was 60-70Gy/30-35F.Chemotherapy plan: Taxol 135 mg·m^-2 at the 1st and 22nd days, Carboplatin AUC=6 g·L^-1·min^-1, at the 1st and 22nd days.The correlation analysis between the grade of level 2 or higher incidence of radioactive lung injury and DVH parameters(V30 and V20)was performed.And according to the whole lung average V30(18.17%)and V20(25.32%), the groups were set up: V30 ≤18%, V30>18% and V20≤25%, V20>25%, and the incidence of levels 2 or higher radioactive lung injury in each group was compared. Results There has positive correlation between levels 2 or higher lung injury classification and V20, V30(r=0.705, P<0.05;r=0.740, P<0.05);the incidence of levels 2 or higher lung injury was respectively 16.67% and 55.56% in V30 ≤ 18.00% group and V30>18.00% group, and there was significant difference(P<0.05);the incidence of levels 2 or higher lung injury was respectively 17.64% and 52.63% in V20 ≤25% and V20 > 25% groups, and there was significant difference(P<0.05). Conclusion V30 and V20 can be used to evaluate and forecast the incidence of radioactive lung injury;when V30>18% and V20>25%, the incidence of radioactive lung injury is significantly increased, and the treatment plan needs to be modified and even the design of treatment plan is given up.

Key words: cancer, non small cell lung, concurrent radiochemotherapy, radioactive lung injury, volume dose parameters

中图分类号:

R734.2

杜敏娟, 姜振宇, 徐晓光, 李洁, 张进. 容积剂量参数V20和V30在评估和预测同步放化疗治疗局部晚期非小细胞肺癌致放射性肺损伤中的应用[J]. 吉林大学学报(医学版), 2015, 41(01): 160-164.

DU Minjuan, JIANG Zhenyu, XU Xiaoguang, LI Jie, ZHANG Jin. Application of V20 and V30 volume dose parameters in evaluating and forecasting radioactive lung injury caused by concurrent radiochemotherapy in treatment of locally advanced non-small cell lung cancer[J]. Journal of Jilin University Medicine Edition, 2015, 41(01): 160-164.

参考文献

[1] 杨新华,钟兰俊,李延特,等. 紫杉醇和顺铂加放疗同步治疗Ⅲ期非小细胞肺癌临床观察 [J].中国肿瘤临床与康复,2007,12(12):163-165.

[2] 仇晓军,马剑波,季斌,等.康莱特加同步放化疗治疗局部晚期非小细胞肺癌的临床研究 [J].临床肿瘤学杂志,2007,12(2):131-133.

[3] Trotti A,Colevas AD,Setser A,et al.CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment [J].Semin Radiat Oncol,2003,13(3):176-181.

[4] Rodrigues G,Lock M,D'Souza D,et al.Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review [J].Radiother Oncol,2004,71(2):127-138.

[5] Willner J,Jost A, Baier K, et al.A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy [J].Strahlenther Onkol,2003,179(8):548-566.

[6] Tang C,Gomez DR,Wang H,et al.Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer [J].Int J Radiat Oncol Biol Phys,2014,88(2):319-325.

[7] Wang D, Zhu J,Sun J,et al.Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy [J].Clin Transl Oncol,2012,14(12):943-952.

[8] Farr KP,Khalil AA,Knap MM,et al.Development of radiation pneumopathy and generalised radiological changes after radiotherapy are independent negative prognostic factors for survival in non-small cell lung cancer patients [J].Radiother Oncol,2013,107(3):382-388.

[9] Liu Y, Xia T, Zhang W,et al.Variations of circulating endothelial progenitor cells and transforming growth factor-beta-1 (TGF-β1) during thoracic radiotherapy are predictive for radiation pneumonitis [J]. Radiat Oncol,2013,8(1):189-197.

[10] Piotrowski T,Matecka-Nowak M,Milecki P.Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy [J]. Neoplasma,2005,52(1):56-62.

[11] Agrawal S,Kumar S,Lawrence A,et al.Ipsilateral lung dose volume parameters predict radiation pneumonitis in addition to classical dose volume parameters in locally advanced NSCLC treated with combined modality therapy [J].South Asian J Cancer,2014,3(1):13-15.

[12] Appalanaido GK,Arul E,Choung WL.Meta-analysis of incidence of early lung toxicity in 3-dimensional conformal irradiation of breast carcinomas [J].Radiat Oncol,2013,8(1):268-279.

[13] Nomura M,Kodaira T,Furutani K,et al.Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation [J].Br J Radiol,2012,85(1014):813-818.

[14] Kim B,Park HC,Oh D,et al.Development of the DVH management software for the biologically-guided evaluation of radiotherapy plan [J].Radiat Oncol J,2012,30(1):43-48.

[15] Uno T,Isobe K,Kawakami H,et al.Dose-volume factors predicting radiation pneumonitis in patients receiving salvage radiotherapy for postlobectomy locoregional recurrent non-small-cell lung cancer [J].Int J Clin Oncol,2006,11(1):55-59.

[16] Barriger RB,Forquer JA,Brabham JG,et al.A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy [J].Int J Radiat Oncol Biol Phys,2012,82(1):457-462.

[17] 王澜,高超,韩春,等.DVH参数对局部晚期非小细胞肺癌同期化放疗肺损伤的预测价值研究 [J].中华放射医学与防护杂志,2010,30(6):725-727.

[18] 杨阳,闫婧,刘娟,等.胸部放疗放射性肺炎病因学相关因素分析 [J].中华肿瘤防治杂志,2012,19(6): 446-449.

[19] Wang D,Shi J,Liang S,et al.Dose-volume histogram parameters for predicting radiation pneumonitis using receiver operating characteristic curve [J].Clin Transl Oncol,2013,15(5):364-369.

[20] Hoover DA,Reid RH,Wong E,et al.SPECT-based functional lung imaging for the prediction of radiation pneumonitis: a clinical and dosimetric correlation [J].J Med Imaging Radiat Oncol,2014,58(2):214-222.

容积剂量参数V20和V30在评估和预测同步放化疗治疗局部晚期非小细胞肺癌致放射性肺损伤中的应用

Application of V20 and V30 volume dose parameters in evaluating and forecasting radioactive lung injury caused by concurrent radiochemotherapy in treatment of locally advanced non-small cell lung cancer

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	杨巍, 李明成. 人口腔鳞状细胞癌Tca8113细胞过表达WWOX基因的基因表达谱分析及WWOX基因的抑癌作用机制[J]. 吉林大学学报(医学版), 2018, 44(06): 1169-1173.
[2]	李丽静, 臧亚茹, 于文会, 梁君伟, 佟艳军. 化疗联合斑蝥酸钠维生素B6注射液对非小细胞肺癌患者的治疗效果及其机制[J]. 吉林大学学报(医学版), 2018, 44(06): 1286-1290.
[3]	袁虎勤, 李强. 水飞蓟素对人胃癌SGC 7901细胞增殖、迁移和侵袭的抑制作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(05): 988-993.
[4]	孟琳, 王璐, 布文奂, 丁鑫鑫, 高华丽, 王梓霖, 刘玉兰, 李琛, 孙宏晨. 小鼠骨髓间充质干细胞对人舌鳞状细胞癌Cal27细胞的归巢作用及其对Cal27细胞增殖和迁移的促进作用[J]. 吉林大学学报(医学版), 2018, 44(05): 891-896.
[5]	孙洪帅, 朱华, 高海燕, 万广财, 于秀艳. 肿瘤标志物SCC-Ag、CEA、CYFRA21-1和D-二聚体联合检测对非小细胞肺癌的早期诊断价值[J]. 吉林大学学报(医学版), 2018, 44(05): 1020-1024.
[6]	魏佳, 王瑶琪, 孙旭, 逄仁柱, 杨帅, 石亮, 李勇, 孟宪瑛. 甲状腺癌相关基因及其在临床诊断中应用的研究进展[J]. 吉林大学学报(医学版), 2018, 44(04): 880-885.
[7]	王淼, 母润红, 李明成, 李洪杰. RNAi沉默survivin和HIF-1α基因对胃癌BGC-823细胞体外增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2018, 44(04): 753-758.
[8]	董洁, 王旭, 崔久嵬. DNA损伤修复通路基因多态性与铂类药物治疗非小细胞肺癌敏感性及预后关系的研究进展[J]. 吉林大学学报(医学版), 2018, 44(04): 869-874.
[9]	李晓, 邱香, 马振卉, 田亚萍. 皮肤转移癌伴发带状疱疹1例报告并文献复习[J]. 吉林大学学报(医学版), 2018, 44(04): 825-827.
[10]	严齐会, 朱慧勇. 转录因子KLFs家族与口腔鳞状细胞癌关系的研究进展[J]. 吉林大学学报(医学版), 2018, 44(03): 679-683.
[11]	赵艳杰, 宋清坤, 李军, 何永明, 曲宸绪. 食管鳞状细胞癌高发区人群食用腌肉与食管鳞状细胞癌风险的关系[J]. 吉林大学学报(医学版), 2018, 44(03): 656-660.
[12]	杨文延, 刘强, 孙志娟, 杜利清, 徐畅, 王彦, 柳杨, 王芹. 褪黑素对人非小细胞肺癌H1299细胞辐射敏感性的影响[J]. 吉林大学学报(医学版), 2018, 44(03): 532-536.
[13]	全晓月, 刘百龙, 刘敏, 董丽华. 阿帕替尼治疗无法耐受化疗的肺鳞状细胞癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(03): 624-627.
[14]	李波, 刘可可, 段浩博, 王远萍, 唐思嘉, 周乐, 孙宏晨. 肿瘤相关巨噬细胞在口腔鳞状细胞癌发生发展中作用及其靶向治疗的研究进展[J]. 吉林大学学报(医学版), 2018, 44(03): 684-688.
[15]	刘霞, 齐凤杰, 杜晓媛. 沉默CRAF基因表达对肝癌细胞侵袭和迁移的影响[J]. 吉林大学学报(医学版), 2018, 44(03): 521-525.